Bone minerals refer to the inorganic compound of the bone tissue that helps in strengthening the bones with its plate and globular structures. These are dynamic in living beings formed from carbonated hydroxyapatite and are continuously reabsorbed and build a new in the bone remodeling process. Bone mineral metabolism maintains a sufficient concentration of inorganic ions in blood serum irrespective of muscle tissue metabolic activities. Furthermore, Bone and mineral metabolism disorder is the term used to describe various conditions that make bones weak. Additionally, Progressive chronic kidney disease, especially end-stage renal disease (ESRD), is responsible for adverse changes in bone and mineral metabolism.
Market Dynamics
The rising prevalence of Chronic Kidney Diseases (CKD) and metabolic diseases along with the increasing ageing population and obese patients is supporting the market growth. The presence of local and multinational players with wide variety of product offerings that helps in boosting bone and mineral metabolism disorders treatment is additionally supporting the market value. The growing awareness about the management of bone and mineral metabolism disorders among healthcare professionals as well as increased access to diagnosis are additionally bolstering the market growth.
On the other side, high cost associated with the management of comorbidities, noncompliance with the treatment protocols, and side effects associated with drugs are some of the factors likely to hamper the market growth during the forecast timeframe from 2020 to 2027.
North America accounted for the maximum revenue share in the Bone and Mineral Disorders Market
In 2019, North America leading the bone and mineral disorders market with maximum share (%) in terms of revenue (US$ Mn). The presence of major players in the region along with the increasing number of elder population is supporting the regional market value. The increasing number of patients with chronic diseases is further supporting the regional market value. According to the national kidney foundation (NKF) estimates of 2019, 15% of US adults i.e. 37 million adults in the United States are estimated to have chronic kidney disease (CKD) and millions of others are at increased risk. Additionally, 1 in 2 people with very low kidney function who are not on dialysis do not know they have CKD.
Asia Pacific is projected to exhibit fastest growth over the forecast period from 2020 to 2027
Asia Pacific is projected to exhibit the fastest growth over the forecast period from 2020 to 2027. The developing economies of the region including China and India are contributing to the regional market value. The increasing investment by the major players in the healthcare sector due to increasing spending by customers is propelling the regional market value.
The players profiled in the report include AbbVie Inc., Amgen Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Sanofi, Shire, and Warner Chilcott LLC. The major bone and mineral disorders players were involved in strategic developments for escalating the profit share in regional as well as the global market. The major investments were announced in the bone and mineral disorders market for technological advancements along with the changing consumer lifestyle.
Market Segmentation
Market By Type of Disorder
Osteomalacia
Osteoporosis
Osteopenia
Rickets
Chronic kidney disease-associated mineral and bone disorders (CKD-MBD)
Paget’s disease of the bone
Osteogenesis imperfect
Others
Market By Medication Type
Bisphosphonates
Estrogens
Phosphate Binders
Non-Calcium, Non-Metal-Based Binder
Metal-Based Binders
Magnesium-Based Binders
Vitamin D Analogs and Supplements
Calcimimetic agents
Calcium and Magnesium Supplements
Market By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
Market By Geography
North America
Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Chapter 1. Industry Overview of Bone and Mineral Disorders
1.1 Definition and Scope
1.1.1 Definition of Bone and Mineral Disorders
1.1.2 Market Segmentation
1.1.3 Years Considered for the Study
1.1.4 Assumptions and Acronyms Used
1.1.4.1 Market Assumptions and Market Forecast
1.1.4.2 Acronyms Used In Global Bone and Mineral Disorders Market
1.2 Summary
1.2.1 Executive Summery
1.2.2 Bone and Mineral Disorders Market By Type of Disorder
1.2.3 Global Bone and Mineral Disorders Market By Medication Type
1.2.4 Global Bone and Mineral Disorders Market By Distribution Channel
1.2.5 Global Bone and Mineral Disorders Market by Regions
Chapter 2. Research Approach
2.1 Methodology
2.1.1 Research Programs/By Distribution Channel
2.1.2 Market Size Estimation
2.1.3 Market Breakdown and Data Triangulation
2.2 Data Source
2.2.1 Secondary Sources
2.2.2 Primary Sources
Chapter 3. Market Dynamics and Competition Analysis
3.1 Market Drivers
3.1.1 Driver 1
3.1.2 Driver 2
3.2 Restraints and Challenges
3.2.1 Restraint 1
3.2.2 Restraint 2
3.3 Growth Opportunities
3.3.1 Opportunity 1
3.3.2 Opportunity 2
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitute
3.4.4 Threat of New Entrants
3.4.5 Degree of Competition
3.5 Market Concentration Ratio And Market Maturity Analysis of Bone and Mineral Disorders Market
3.5.1 Go To Market Strategy
3.5.1.1 Introduction
3.5.1.2 Growth
3.5.1.3 Maturity
3.5.1.4 Saturation
3.5.1.5 Possible Development
3.6 Technological Roadmap for Bone and Mineral Disorders Market
3.7 Value Chain Analysis
3.7.1 List of Key Manufacturers
3.7.2 List of Customers
3.7.3 Level of Integration
3.8 Cost Structure Analysis
3.8.1 Price Trend of Key Raw Materials
3.8.2 Raw Material and Suppliers
3.8.3 Proportion of Manufacturing Cost Structure
3.8.3.1 Raw Material
3.8.3.2 Labor Cost
3.8.3.3 Manufacturing Expense
3.9 Regulatory Compliance
3.10 Competitive Landscape, 2019
3.10.1 Player Positioning Analysis
3.10.2 Key Strategies Adopted By Leading Players
Chapter 4. Manufacturing Plant Analysis
4.1 Manufacturing Plant Location and Establish Date of Global Bone and Mineral Disorders Major Manufacturers in 2019
4.2 R&D Status and By Medication Type Source of Global Bone and Mineral Disorders Major Manufacturers in 2019
Chapter 5. Bone and Mineral Disorders Market By Type of Disorder
5.1 Introduction
5.2 Global Bone and Mineral Disorders Revenue (US$ Mn) by Type of Disorder
5.2.1 Global Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 – 2027
5.2.2 Osteomalacia
5.2.2.1 Osteomalacia Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.3 Osteoporosis
5.2.3.1 Osteoporosis Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.4 Osteopenia
5.2.4.1 Osteopenia Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.5 Rickets
5.2.5.1 Rickets Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.6 Chronic kidney disease-associated mineral and bone disorders (CKD-MBD)
5.2.5.1 Chronic kidney disease-associated mineral and bone disorders (CKD-MBD) Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.7 Paget’s disease of the bone
5.2.5.1 Paget’s disease of the bone Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.8 Osteogenesis imperfect
5.2.5.1 Osteogenesis imperfect Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.9 Others
5.2.5.1 Others Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.3 Market Attractive Analysis By Type of Disorder 2019
Chapter 6. Bone and Mineral Disorders Market By Medication Type
6.1 Introduction
6.2 Global Bone and Mineral Disorders Revenue (US$ Mn) by Medication Type
6.2.1 Global Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 – 2027
6.2.2 Bisphosphonates
6.2.2.1 Bisphosphonates Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
6.2.3 Estrogens
6.2.3.1 Estrogens Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
6.2.4 Phosphate Binders
6.2.4.1 Phosphate Binders Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
6.2.5 Non-Calcium, Non-Metal-Based Binder
6.2.4.1 Non-Calcium, Non-Metal-Based Binder Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
6.2.6 Metal-Based Binders
6.2.4.1 Metal-Based Binders Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
6.2.7 Magnesium-Based Binders
6.2.4.1 Magnesium-Based Binders Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
6.2.8 Vitamin D Analogs and Supplements
6.2.4.1 Vitamin D Analogs and Supplements Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
6.2.9 Calcimimetic agents
6.2.4.1 Calcimimetic agents Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
6.2.10 Calcium and Magnesium Supplements
6.2.4.1 Calcium and Magnesium Supplements Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
6.3 Market Attractive Analysis By Medication Type 2019
Chapter 7. Bone and Mineral Disorders Market By Distribution Channel
7.1 Introduction
7.2 Global Bone and Mineral Disorders Revenue (US$ Mn) by Distribution Channel
7.2.1 Global Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 – 2027
7.2.2 Hospital Pharmacies
7.2.2.1 Hospital Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
7.2.3 Retail Pharmacies
7.2.3.1 Retail Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
7.2.4 Online Pharmacies
7.2.4.1 Online Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
7.2.5 Drug Stores
7.2.6 Drug Stores Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
7.3 Market Attractive Analysis By Distribution Channel 2019
Chapter 8. North America Bone and Mineral Disorders Market By Country
8.1 North America Bone and Mineral Disorders Market Overview
8.2 U.S.
8.2.1 U.S. Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
8.2.2 U.S. Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
8.2.3 U.S. Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
8.3 Canada
8.3.1 Canada Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
8.3.2 Canada Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
8.3.3 Canada Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
8.4 North America PEST Analysis
Chapter 9. Europe Bone and Mineral Disorders Market By Country
9.1 Europe Bone and Mineral Disorders Market Key Overview
9.2 UK
9.2.1 UK Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
9.2.2 UK Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
9.2.3 UK Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.3 Germany
9.3.1 Germany Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
9.3.2 Germany Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
9.3.3 Germany Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.4 France
9.4.1 France Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
9.4.2 France Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
9.4.3 France Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.5 Spain
9.5.1 Spain Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
9.5.2 Spain Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
9.5.3 Spain Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.6 Rest of Europe
9.6.1 Rest of Europe Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
9.6.2 Rest of Europe Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
9.6.3 Rest of Europe Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
9.7 Europe PEST Analysis
Chapter 10. Asia-Pacific Bone and Mineral Disorders Market By Country
10.1 Asia Pacific Bone and Mineral Disorders Market Overview
10.2 China
10.2.1 China Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
10.2.2 China Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
10.2.3 China Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027 105
10.3 Japan
10.3.1 Japan Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
10.3.2 Japan Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
10.3.3 Japan Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.4 India
10.4.1 India Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
10.4.2 India Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
10.4.3 India Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.5 Australia
10.5.1 Australia Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
10.5.2 Australia Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
10.5.3 Australia Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.6 South Korea
10.6.1 South Korea Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
10.6.2 South Korea Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
10.6.3 South Korea Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.7 Rest of Asia-Pacific
10.7.1 Rest of Asia Pacific Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
10.7.2 Rest of Asia Pacific Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
10.7.3 Rest of Asia Pacific Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.8 Asia Pacific PEST Analysis
Chapter 11. Latin America Bone and Mineral Disorders Market By Country
11.1 Latin America Bone and Mineral Disorders Market Overview
11.2 Brazil
11.2.1 Brazil Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
11.2.2 Brazil Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
11.2.3 Brazil Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.3 Mexico
11.3.1 Mexico Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
11.3.2 Mexico Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
11.3.3 Mexico Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.4 Rest of Latin America
11.4.1 Rest of Latin America Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
11.4.2 Rest of Latin America Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
11.4.3 Rest of Latin America Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.5 Latin America PEST Analysis
Chapter 12. Middle East & Africa Bone and Mineral Disorders Market By Country
12.1 Middle East & Africa Bone and Mineral Disorders Market Overview
12.2 Saudi Arabia
12.2.1 Saudi Arabia Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
12.2.2 Saudi Arabia Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
12.2.3 Saudi Arabia Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
12.3 UAE
12.3.1 UAE Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
12.3.2 UAE Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
12.3.3 UAE Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
12.4 Rest of Middle East & Africa
12.4.1 Rest of Middle East & Africa Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Type of Disorder, 2016 - 2027
12.4.2 Rest of Middle East & Africa Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Medication Type, 2016 - 2027
12.4.3 Rest of Middle East & Africa Bone and Mineral Disorders Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
12.5 South Africa PEST Analysis
Chapter 13. Player Analysis of Bone and Mineral Disorders
13.1 Global Bone and Mineral Disorders Market Company Share Analysis
13.2 Competition Matrix
13.2.1 Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2 New Product Launches and Product Enhancements
13.2.3 Mergers And Acquisition In Global Bone and Mineral Disorders Market
13.2.4 Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
Chapter 14. Company Profile
14.1 AbbVie Inc.
14.1.1 Company Snapshot
14.1.2 Business Overview
14.1.3 Financial Overview
14.1.3.1 Revenue (US$ Mn), 2019
14.1.3.2 AbbVie Inc. 2019 Bone and Mineral Disorders Business Regional Distribution
14.1.4 Product/Service and Specifications
14.1.5 Recent Development & Business Strategy
14.1.6 Manufacturing Plant Footprint Analysis
14.2 Amgen Inc.
14.3 F. Hoffmann-La Roche Ltd
14.4 Merck & Co., Inc.
14.5 Novartis AG
14.6 Roche
14.7 Sanofi
14.8 Shire
14.9 Warner Chilcott LLC
14.10 Others
